The Effects Of The Atorvastatin And The Serum Levels Of BDNF On Clinical Effectiveness In Patients With Acute Cerebral Infarction

Objective: This content of atorvastatin treatment on patients with acute cerebral infar-ction is observed with serum brain-derived neurotrophic factor (BDNF), degree ofneurological deficits and activities of daily living, and to explore whether treatment ofacute stroke with atorvastatin promotes functional recovery associated with stroke andinduces BDNF expression, which upregulation may contributes toAtorvastatin-mediated functional benefit.Methods: Stroke patients were randomly divided into groups with and withoutAtorvastatin treatment. atorvastatin treatment group took atorvastatin20mg pernight, aspirin100mg per night and edaravone(liquid medicine) treatment in hospital,after the discharge continued taking atorvastatin and aspirin as the original program,the total course of six weeks. Atorvastatin-untreated group only took aspirin100mg pernight and edaravone(liquid medicine) treatment in hospital, after the discharge，continued taking aspirin as the original program, the total course of six weeks. Serumlevels of BDNF were measured by ELISA. Stroke severity was measured using theNational Institutes of Health Stroke Scale, physical disability was measured with theActivity of Daily Living Scale (ADL). Scores on the NIHSS and ADL were obtained atadmission, at6week assessment points.Results: The test, at first observating50patients with acute cerebral infarction, aborted4cases of Atorvastain-treatment,5cases of Atorvastatin-untreated, owing to their own exit or changes in condition. Thus21cases of Atorvastain-treatment,20cases ofAtorvastatin-untreated are data integrity into the analysis. The difference of possibleprognostic factors in the two groups, such as gender, age, past history, time of onset,daily living skills and nerve function defect, was not statistically significant. The serumlevels of BDNF in the both groups after the treatment are higher than that before thetreatment(P﹤0.001); The BDNF levels in Atorvastain-treatment group are significantlyhigher than that in Atorvastatin-untreated group(P﹤0.05); The NIHSS scores of theboth groups reduced significantly after the treatment compared with the scores beforethe treatment(P﹤0.001). The NIHSS scores in Atorvastain-treatment group are lowerthan that of Atorvastatin-untreated group(P﹤0.05); the ADL scores are significantlyimproved(P﹤0.001), the ADL scores of Atorvastain-treatment group are higher thanAtorvastatin-untreated group(P﹤0.05). Serum BDNF levels and NIHSS scorenegatively correlated(R=－0.656，P=0.000).Conclusion:1. Treatment of acute stroke with atorvastatin could promote functional recoveryassociated with stroke.2. Treatment of acute stroke with atorvastatin could induce BDNF expression.3. BDNF possesses neuroprotective effect in cerebral infarction.4. Atorvastatin can induce the serum BDNF expression in patients with acute cerebralinfarction, which may be one of the mechanisms that promote functional recovery afteracute stroke.